
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Tinengotinib elicited responses with a manageable safety profile in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Covers key factors in deciding on radiation treatment.

Discusses treatment options for advanced metastatic disease.

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Looks at approaches for isolated lymph node involvement.

Examines the considerations for operating on older prostate cancer patients.

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.
























































